Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Posts Tagged ‘obesity’
Digging for the roots of diabetes
Wednesday, December 9, 2009, 7:58 pmEvery year, the number of Americans with diabetes rises by about 1 million and genetic risk factors alone can be blamed for only a small portion of the cases. The 30 to 35 known diabetes genes, as researchers have dubbed them, account for only about 10 percent of the risk that a brother or sister of a diabetic will also develop the disease.
Dr. Ronald Kahn
To better understand the other 90 percent, said Dr. Ronald Kahn, a Harvard University medical professor and vice chairman of the Joslin Diabetes Center, “we have to look at the environment.” Read more…
Next: A crucial decision
Thursday, September 3, 2009, 8:23 amThis is the last part. Continued from part 2.
Getting a ghrelin drug to market
Thursday, September 3, 2009, 8:20 amThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Ghrelin: A new hormone is found
Thursday, September 3, 2009, 8:15 amINTRODUCTION
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.
Next: A crucial decision
Tuesday, July 28, 2009, 9:14 amThis is the last part. Continued from part 2.
Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Getting a ghrelin drug to market
Tuesday, July 14, 2009, 11:38 amThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Ghrelin: A new hormone is found
Monday, July 6, 2009, 9:24 amINTRODUCTION
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.
